Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy

Fig. 4

The Suppression of the ascites BCBL-1 proliferation and the KSHV propagation in vivo by the FIT-039 treatment. A-B Representative images (A) and the frequency plot (B) for the ascites from the PEL xenograft mice at day 43. Human CD38-PE and CD45-APC positive cells are counted as the BCBL-1-derived cells. n = 5 for each group. C-D The KSHV copy number was quantified by the quantitative PCR for PEL chylous ascites (C) and plasma (D) from the BCBL-1 xenograft mice with the FIT-039 treatment. n = 6, n = 5, and n = 6 for vehicle, 75 mpk, and 300 mpk for ascites, and n = 6 each for plasma at the day 45. Mean ± SE are shown; **, p < 0.01; ***, p < 0.001 by one-way ANOVA with Turkey’s multiple comparisons test; #, p < 0.05 by one-tailed Student’s t-test in (B). Mean ± SE are shown; **, p < 0.01; ***, p < 0.001 by two-tailed Student’s t-test in (C) and (D). mpk for mg/kg-BW in (A-D)

Back to article page